Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/57607
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBakay, O.S.K.-
dc.contributor.authorKacar, N.-
dc.contributor.authorGul, B.-
dc.contributor.authorGoksin, S.-
dc.contributor.authorGural, Y.-
dc.date.accessioned2024-07-28T17:17:39Z-
dc.date.available2024-07-28T17:17:39Z-
dc.date.issued2024-
dc.identifier.issn1539-6304-
dc.identifier.urihttps://doi.org/10.2500/aap.2024.45.240041-
dc.identifier.urihttps://hdl.handle.net/11499/57607-
dc.description.abstractBackground: Chronic spontaneous urticaria (CSU) is a common disease with complex pathogenesis. Patients' clinical characteristics and responses to treatment vary. Objective: We aimed to investigate the role of data obtained from routinely recommended tests in predicting the response to omalizumab, the only biologic agent approved for treatment, and in defining the clinical characteristics of the patients. Methods: A retrospective study of patients who started omalizumab treatment for CSU between 2015 and 2022 at the Department of Dermatology, Pamukkale University, was conducted. Response criteria were based on the urticaria control test, and patients with a urticaria control test score <12 at 6 months were considered treatment non-responders. Eosinophil and basophil counts, neutrophil-lymphocyte ratio (NLR), systemic immune inflammation index (SII), systemic inflammation response index (SIRI), and total immunoglobulin E (IgE) levels of the patients were evaluated before treatment and at the sixth month of treatment. Results: A total of 23.1% of the patients were unresponsive to omalizumab. The response rate to the omalizumab treatment of the patients with a total IgE level ≤ 30 IU/L (n = 4 [5.7%]) was significantly lower than patients with total IgE level > 30 IU/L (n = 66 [94.3%]) (p = 0.015). The mean ± standard deviation SIRI levels were significantly higher in non-responders versus responders (1.53 ± 1.03 versus 1.15 ± 7.76; p = 0.026). Eosinophil counts positively correlated with basophil counts (r = 587; p < 0.001) and IgE levels (r = 0.290; p = 0.005) but a negative correlation was found with levels of NLR (r = -0.475; p < 0.001), SIRI (r = -0.259; p = 0.013), and SII (r = -0.285; p = 0.006). NLR levels were lower in CSU patients with atopy, than in those without atopy (1.9 ± 0.9 vs 2.9 ± 2.1, p = 0.022). Conclusion: We suggest that eosinopenia and high NLR levels are linked to autoimmune CSU. Predicting a poor response to omalizumab seems possible with total IgE levels < 30 IU/L and high SIRI levels.en_US
dc.language.isoenen_US
dc.relation.ispartofAllergy and asthma proceedingsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantiallergic agenten_US
dc.subjectimmunoglobulin Een_US
dc.subjectomalizumaben_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectblooden_US
dc.subjectchronic urticariaen_US
dc.subjectdrug therapyen_US
dc.subjecteosinophilen_US
dc.subjectfemaleen_US
dc.subjecthumanen_US
dc.subjectimmunologyen_US
dc.subjectleukocyte counten_US
dc.subjectmaleen_US
dc.subjectmiddle ageden_US
dc.subjectretrospective studyen_US
dc.subjecttreatment outcomeen_US
dc.subjectyoung adulten_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAnti-Allergic Agentsen_US
dc.subjectChronic Urticariaen_US
dc.subjectEosinophilsen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectImmunoglobulin Een_US
dc.subjectLeukocyte Counten_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectOmalizumaben_US
dc.subjectRetrospective Studiesen_US
dc.subjectTreatment Outcomeen_US
dc.subjectYoung Adulten_US
dc.titleWhat can be learned from real-world data about chronic spontaneous urticaria?en_US
dc.typeArticleen_US
dc.identifier.volume45en_US
dc.identifier.issue4en_US
dc.identifier.startpage255en_US
dc.identifier.endpage261en_US
dc.departmentPamukkale Universityen_US
dc.identifier.doi10.2500/aap.2024.45.240041-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.authorscopusid57797495800-
dc.authorscopusid15750610300-
dc.authorscopusid59217389900-
dc.authorscopusid57194194375-
dc.authorscopusid57216618247-
dc.identifier.pmid38982597en_US
dc.identifier.scopus2-s2.0-85198471199en_US
dc.identifier.wosWOS:001267352700012en_US
dc.institutionauthor-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
item.openairetypeArticle-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

1
checked on Oct 13, 2024

WEB OF SCIENCETM
Citations

1
checked on Nov 21, 2024

Page view(s)

20
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.